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Abstract 
Background: We recently reported that bacterial lipopolysaccharide (LPS)-induced inflammation decreases the 
expression of the primary thyroid hormone transporters at the blood–brain barrier, organic anion-transporting 
polypeptide 1c1 (OATP1c1) and monocarboxylate transporter 8 (MCT8). l-type amino acid transporters 1 and 2 (LAT1 
& LAT2) are regarded as secondary thyroid hormone transporters, and are expressed in cells of the blood–brain or 
blood-cerebrospinal fluid barrier and by neurons. The purpose of this study was to examine the effect of LPS-induced 
inflammation on the expression of LAT1 and LAT2, as these may compensate for the downregulation of OATP1c1 and 
MCT8.
Methods: LPS (2.5 mg/kg body weight) was injected intraperitoneally to adult, male, Sprague–Dawley rats and 
C57Bl/6 mice, which were euthanized 2, 4, 9, 24 or 48 h later. LAT1 and LAT2 mRNA expression were studied on 
forebrain sections using semiquantitative radioactive in situ hybridization. LAT1 protein levels in brain vessels were 
studied using LAT1 immunofluorescence. Statistical comparisons were made by the non-parametric Kruskal–Wallis 
and Dunn’s tests.
Results: In both species, LAT1 mRNA decreased in brain blood vessels as soon as 2 h after LPS injection and was 
virtually undetectable at 4 h and 9 h. During recovery from endotoxemia, 48 h after LPS injection, LAT1 mRNA in brain 
vessels increased above control levels. A modest but significant decrease in LAT1 protein levels was detected in the 
brain vessels of mice at 24 h following LPS injection. LPS did not affect LAT1 and LAT2 mRNA expression in neurons 
and choroid plexus epithelial cells.
Conclusions: The results demonstrate that LPS-induced inflammation rapidly decreases LAT1 mRNA expression at 
the blood–brain barrier in a very similar manner to primary thyroid hormone transporters, while changes in LAT1 pro-
tein level follow a slower kinetics. The data raise the possibility that inflammation may similarly down-regulate other 
blood–brain barrier transport systems at the transcriptional level. Future studies are required to examine this pos-
sibility and the potential pathophysiological consequences of inflammation-induced changes in blood–brain barrier 
transport functions.
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Background
Circulating thyroid hormone (TH) enters the brain via 
the blood–brain and blood-cerebrospinal fluid barriers 
[1], by means of specific transporter proteins expressed 
in the membranes of cerebral endothelial cells and cho-
roid plexus epithelial cells [2, 3]. Recent knockout mouse 
models provided evidence that TH entry into the brain 
is largely dependent on two TH transporters, monocar-
boxylate transporter 8 (MCT8) and organic anion-trans-
porting polypeptide 1c1 (OATP1c1) [4–9]. We recently 
described that during systemic inflammation induced 
by bacterial lipopolysaccharide (LPS) administration, 
OATP1c1 and MCT8 mRNAs, as well as OATP1c1 pro-
tein markedly decrease in brain vessels [10]. The down-
regulation of these transporters at the blood–brain 
barrier would suggest reduced TH uptake into the brain 
and consequently, lower brain TH concentration, espe-
cially during prolonged systemic inflammatory states.
Other than MCT8 and OATP1c1, however, there are 
additional membrane proteins that are capable of trans-
porting TH and may contribute to TH homeostasis in the 
brain [11, 12]. Included are type 1 and 2 L-type amino 
acid transporters (LAT1 or Slc7a5; LAT2 or Slc7a8) that 
transport TH with low to medium affinity [11, 13] and 
are expressed in multiple brain cell types. In vivo mouse 
and rat studies demonstrated that LAT1 is expressed in 
microvascular cells of the blood–brain barrier [12, 14–
18], choroid plexus epithelial cells [14, 18] (in rats but 
not mice) and neurons [12], whereas LAT2 is expressed 
in neurons [12, 19, 20] and the choroid plexus [12, 19]. 
Therefore, LAT1 and LAT2 may contribute to TH trans-
port across the blood–brain and blood-cerebrospinal 
fluid barriers and facilitate neuronal uptake and/or 
release of TH.
To determine whether upregulation of LAT1 and 
LAT2 compensates for the downregulation of MCT8 and 
OATP1c1 during inflammation and offsets the effect of 
reduced brain TH uptake on neurons, we examined the 
effect of LPS on LAT1 and LAT2 expression in the mouse 
and rat forebrain using in  situ hybridization to study 
LAT1 and LAT2 mRNAs in a cell-type specific-manner, 




The experiments were carried out on adult, male, 
Sprague–Dawley rats (Taconic Biosciences, German-
town, NY, USA) of similar age, weighing 220–260 g, and 
adult, male, C57Bl/6 mice (Taconic) of similar age, weigh-
ing 19–21 g. Animals were housed under standard condi-
tions (lights on between 0600 and 1800  h, temperature 
22 ± 1 °C, rodent chow and water ad libitum). Only male 
animals were used in this study to avoid the potential 
confounding effects of the estrous cycle on the experi-
mental results. All experimental protocols were reviewed 
and approved by the Institutional Animal Care and Use 
Committee at Tufts Medical Center (Protocol# B2012-
171) and was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health.
Injections and tissue preparation
LPS-injections Animals were injected ip with LPS from 
Escherichia coli (serotype O55:B5; Sigma-Aldrich Co., 
St. Louis, MO, USA) between 9 and 11 a.m. LPS was dis-
solved in saline, and injected at a dose of 2.5 mg/kg body 
weight to all animals. Control animals received the same 
volume of saline. In our experience, different LPS sero-
types such as O55:B55 and O127:B8 elicit very similar 
inflammatory responses in the brain, including upregula-
tion of type 2 deiodinase [21, 22].
Time course experiment for in situ hybridization in rats 
and mice Groups of animals containing 4 or 5 rats or 
mice were injected with LPS, and 2, 4, 9, 24 or 48 h later 
were anesthetized with ketamine-xylazine (ketamine: 
75 mg/kg body weight; xylazine: 10 mg/kg body weight), 
then decapitated. Control mice were euthanized at 9  h 
(n = 5), control rats at either 9 h (n = 3) or 24 h (n = 2), 
based on previous experiments. The intensity of hybridi-
zation and immunofluorescence signals were very similar 
in all control rats. The brains were removed, snap-frozen 
on powdered dry ice and 16 μm thick coronal sections 
from the forebrain were cut using a Leica CM3050 S cry-
ostat (Leica Microsystems, Nussloch GmbH, Germany). 
Sections were thaw-mounted on Superfrost Plus slides 
(Fisher Scientific Co., Pittsburgh, PA, USA), air-dried and 
stored at −80 °C until processed for in situ hybridization 
or immunofluorescence.
Generation of hybridization probes
Template cDNA fragments were generated with RT-
PCR using standard procedures. Amplification was per-
formed on cDNA synthesized from rat and mouse brain 
for LAT1 and rat and mouse liver for LAT2. Fragments 
were cloned into pGEM®-T vector (Promega) and con-
firmed by sequencing. Probe sequences were as follows: 
rat LAT1 probe corresponds to nt 64–851 of [GenBank: 
NM_017353.1]; mouse LAT1 probe nt 81–868 of [Gen-
Bank: NM_011404.3]; rat LAT2 probe nt 621–1368 
of [GenBank: NM_053442.1]; mouse LAT2 probe nt 
657–1335 of [GenBank: NM_016972.2]. Antisense and 
sense riboprobes were synthesized using SP6 or T7 RNA 
polymerase (Promega) in the presence of [35S]-uridine 
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5′-(alpha-thio) triphosphate (PerkinElmer), and puri-
fied with Mini Quick Spin RNA columns (Roche Applied 
Sciences).
Isotopic in situ hybridization
Isotopic in  situ hybridization was performed as pre-
viously described for fresh frozen sections [23] using 
50,000  cpm/μl radiolabeled probe concentrations. Fol-
lowing stringency washes, sections were dehydrated in 
ascending ethanol series, air-dried and placed on Amer-
sham Hyperfilm autoradiography film (GE Healthcare 
Biosciences) for 7 days. Slides were then dipped in Kodak 
NTB autoradiography emulsion (Carestream Health 
Inc) and stored at 4  °C until developed. Exposure times 
were as follows: 14 days for rat LAT1; 17 days for mouse 
LAT1; 14 days for rat LAT2 and 21 days for mouse LAT2. 
Autoradiograms were developed with Kodak D19 devel-
oper (Eastman Kodak Co). Sections were immersed in 
0.0005 % cresyl violet acetate (Sigma-Aldrich) for 2 min 
to obtain fluorescent labeling of cell nuclei, dehydrated in 
ascending ethanol series and xylenes, and coverslipped 
with DPX (Sigma-Aldrich). Hybridizations with the sense 
transcripts for each probe did not yield any signal above 
a low-level of homogenous background. Darkfield images 
of the emulsion autoradiographs were captured using 
a Zeiss Axioplan 2 microscope equipped with a SPOT 
Slider digital camera (Diagnostic Instruments).
Isotopic LAT1 in situ hybridization combined 
with immunofluorescence
To confirm that LAT1 mRNA is expressed in both 
microvascular cells and neurons, sections from con-
trol rat and mouse brains were hybridized for LAT1 as 
above, then processed further for immunofluorescence. 
The sections were treated with the mixture of 0.5 % Tri-
ton X-100 and 0.5  % H2O2 for 15  min, rinsed in phos-
phate-buffered saline (PBS) (3  ×  10  min), immersed 
in maleate buffer (pH 7.5) for 10  min and then in 1  % 
blocking reagent for nucleic acid hybridization (Roche). 
To visualize neuronal cell bodies and blood vessels, sec-
tions were incubated in the mixture of a mouse mono-
clonal antibody against the neuronal proteins HuC/HuD 
(Life Technologies; Cat# A21271, raised against human 
HuC/HuD; used at 1 µg/ml) and polyclonal chicken IgY 
against vimentin (Millipore; Cat# AB5733, raised against 
recombinant vimentin; used at 1:4000 dilution). Other 
sections were incubated in a rabbit polyclonal antibody 
against LAT1 (Cosmo Bio Co., Ltd., Tokyo, Japan; Cat# 
KAL-KE026, diluted at 1  µg/ml) to label microvascu-
lar cells. The primary antibodies were detected with 
Alexa Fluor 488-conjugated donkey anti-mouse IgG 
(Life Technologies; 1:200), Cy3-conjugated donkey anti-
chicken IgG (Jackson ImmunoResearch, West Grove, 
PA, USA) and Cy3-conjugated donkey anti-rabbit IgG 
(Jackson; 1:200). Sections were then dehydrated, dipped 
in Kodak NTB autoradiography emulsion, and the auto-
radiograms were developed after 17  days. The mouse 
HuC/D antibody and the chicken vimentin antibody 
have been used extensively for immunofluorescent stud-
ies (see references [22, 24–26]). The HuC/D antiserum 
labeled neuronal cell bodies, vimentin immunostaining 
labeled pericytes in the brain vasculature [27] as well as 
ependymal and meningeal cells.
Immunofluorescence
For LAT1 immunofluorescence, fresh-frozen mounted 
sections were fixed with methanol at −20  °C for 5 min. 
While LAT1 immunostaining also worked well with 
standard 4  % paraformaldehyde fixation, methanol fixa-
tion produced more intense signal and less background 
staining. Sections were permeabilized with 0.25  % Tri-
ton-X-100 for 20 min, and then blocked with 2 % normal 
horse serum in PBS for 20 min. Sections were incubated 
overnight in a rabbit antiserum against human LAT1 
(Cosmo Bio Co., Ltd., Cat# KAL-KE026, diluted at 1 µg/
ml), which was subsequently detected with Cy3-conju-
gated donkey anti-rabbit IgG (Jackson Immunoresearch, 
1:200).
To demonstrate that LAT1 is expressed in endothelial 
cells, dual immunfluorescence was performed for LAT1 
and either CD31 (or PECAM-1) or glucose transporter 1 
(GLUT1), both regarded as markers for endothelial cells. 
To label CD31, a monoclonal rat antibody against CD31 
(Cat# 550274; clone MEC 1.3; BD Biosciences, Franklin 
Lakes, NJ, USA) was used at 0.3  µg/ml concentration 
and subsequently detected with Alexa Fluor 488-conju-
gated donkey anti-rat IgG (Jackson; 1:400). For GLUT1, 
a monoclonal mouse antibody against GLUT1 (Cat# 
MABS132; clone 5B12.3; Millipore) was used at 0.5  µg/
ml concentration and subsequently detected with Alexa 
Fluor 488-conjugated donkey anti-mouse IgG (Life Tech-
nologies; 1:400).
LAT2 immunofluorescence was performed according 
to the same methanol fixation protocol as above using a 
rabbit polyclonal antiserum against mouse LAT2 (Cat# 
0142-10; ImmunoGlobe Antikörpertechnik GmBH, Him-
melstadt, Germany; diluted at 2 µg/ml), and subsequently 
Cy3-conjugated donkey anti-rabbit IgG (Jackson). This 
antiserum was used previously for immunohistochemis-
try in the mouse brain [20].
Validation of the specificity of the LAT1 antiserum
The LAT1 polyclonal antiserum (Cosmo-Bio Co., Cat# 
KAL-KE026) was raised against the C-terminal 14 amino 
acids of human LAT1 (amino acid sequence: CTVL-
CQKLMQVVPQET) [28], which differs in only one 
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amino acid from the mouse/rat sequence. On Western 
blots from the rat and mouse brain (see Additional file 1 
for immunoblotting methods), the antibody recognized 
a single band corresponding to a molecular weight of 
approximately 46  kDa (Additional file  2), in agreement 
with a previous report [14]. LAT1 immunofluorescence 
resulted in intense staining of brain vessels and gener-
ally no parenchymal labeling, in accordance with previ-
ous immunostaining studies in mice and rats [14–18]. 
The high specificity of the immunostaining was further 
confirmed by identical LAT1 immunostaining and in situ 
hybridization patterns in specific regions such as the 
subcomissural organ, where intense LAT1 immunostain-
ing was previously reported [15], and in the caudal part 
of the rat dorsal third ventricle, where we observed a 
very characteristic pattern of cells expressing high lev-
els of LAT1 mRNA and protein surrounding the choroid 
plexus (see Additional file 2).
Image analysis
Immunofluorescent images were captured using the 
following fluorescent filter sets: for Cy3, excitation of 
540–590  nm, bandpass of 595  nm, and emission of 
600–660  nm; for Alexa 488, excitation of 460–500  nm, 
bandpass of 505 nm, and emission of 510–560 nm. Semi-
quantitative image analysis was performed with ImageJ 
software (public domain at http://rsb.info.nih.gov/ij). 
In situ hybridization and immunofluorescent signals 
were compared between sections from a single experi-
ment where all conditions were identical. Vascular LAT1 
hybridization signal was quantified in the rat cortex 
where parenchymal hybridization signal is lower than in 
other forebrain regions, and thus, the more intense vas-
cular signal could be easily distinguished. On darkfield 
images taken with a 5×  objective, the intense vascular 
signal was separated from the low-level parenchymal 
signal using the threshold tool in ImageJ, and the area 
covered by the vascular signal was measured. LAT1 
immunofluorescence in blood vessels was quantified on 
images taken with a 10× objective from the same regions 
of the mouse or rat cortex, hypothalamus and thalamus. 
Immunolabeled vessels were separated from the back-
ground using the threshold tool, and the average pixel 
intensity (brightness value) of the immunofluorescent 
signal was measured. Analyses from all brain regions 
yielded the same results, and data from the hypothala-
mus are presented.
Statistical analysis
Data are presented as mean ± SEM. Groups were com-
pared by the non-parametric Kruskal–Wallis test, and 
then post hoc comparisons between the LPS-treated 
groups vs. the control group were made by Dunn’s test.
Results
Distribution of LAT1 mRNA in the rat and mouse forebrain
LAT1 in situ hybridization patterns were highly similar in 
rats and mice. In general, intense hybridization signal was 
associated with blood vessels, including major vessels 
penetrating the brain surface and smaller vessels and cap-
illaries (Figs. 1, 2B, C). This is in agreement with reported 
data that LAT1 mRNA is highly enriched in brain vessels 
[12, 18, 29, 30]. Parenchymal, non-vascular hybridization 
signal was generally less intense than the vascular signal, 
and only rarely resulted in the formation of well-defined 
silver grain clusters under the used experimental condi-
tions. This parenchymal signal closely corresponded to 
the distribution pattern of different neuronal popula-
tions, and we confirmed that it was associated primarily 
with neuronal cell bodies (Fig.  1A); however, we can-
not exclude that other cell types also contributed to the 
parenchymal signal. Neuronal LAT1 hybridization was 
more prominent in most hypothalamic nuclei, the medial 
habenular nucleus of the thalamus, certain amygdalar 
regions, hippocampal principal cell layers and pyriform 
cortex, whereas only light signal labeled most of the 
cortical areas and several thalamic nuclei (Fig.  2A). The 
choroid plexus was labeled with moderate hybridization 
signal in rats (Fig. 2A), while it was not labeled in mice, in 
agreement with previous mRNA studies [12, 14]. Inter-
estingly, in the rat, cells with very intense hybridization 
signal were located alongside the choroid plexus of the 
dorsal third ventricle; caudally, these cells almost encir-
cled the choroid plexus (see Additional file 2). Hybridiza-
tion signal also labeled the subfornical and subcomissural 
organs (see Additional file  2), while hypothalamic tany-
cytes were not labeled.
Effect of LPS on LAT1 mRNA
Following LPS administration, LAT1 mRNA decreased 
markedly in blood vessels of both rats and mice, in all 
regions of the forebrain. The time course of this response 
is illustrated in Figs.  2 and 3; quantification of this 
response by image analysis is presented in Fig.  4A. In 
rats, vascular hybridization signal decreased at 2 h after 
LPS. At this point, LAT1 mRNA was not detected in 
major vessels, only in smaller vessels and capillaries, but 
fewer than in controls (Fig.  2B). Hybridization signal in 
vessels could only occasionally be discerned at 4 and 9 h 
after LPS (Figs. 2B, 3A). At 24 h, the vascular labeling re-
appeared but was still lower than in control rats (Fig. 2B). 
Forty-eight hours after LPS administration, the vascular 
signal was conspicuously and markedly higher than con-
trol levels in 3 out of 4 rats. In these rats, the hybridi-
zation signal was generally more intense in individual 
vessels and labeled a greater portion of the vasculature 
than in control rats (Figs. 2A, B, 3A). One rat in the 48 h 
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group had signal levels comparable to the control group. 
This difference is probably due to the variation in the tim-
ing of the recovery phase after endotoxemia, and is remi-
niscent of the post-endotoxemic increase of OATP1c1 
mRNA levels that could occur either 24  h or 48  h after 
LPS [10]. In mice, blood vessel-associated hybridization 
signal was only occasional or very light at 2 h and 24 h 
after LPS, and was completely absent in the 4 h and 9 h 
LPS groups (Figs. 2C, 3C). Similar to rats, in the 48 h LPS 
group, 3 mice had increased vascular LAT1 hybridization 
signal than controls, and 1 mouse had signal levels com-
parable to controls (Figs. 2C, 3C).
Parenchymal, neuronal LAT1 hybridization signal 
remained stable in forebrain regions at any time after LPS 
administration in both species (Figs. 2A, 3). LAT1 mRNA 
expression in the rat choroid plexus also did not change 
after LPS injection.
Effect of LPS on LAT1 protein
LAT1 immunofluorescence labeled brain blood vessels in 
both species. Using dual immunofluorescence, we dem-
onstrated that LAT1 in vessels always colocalized with 
the endothelial markers CD31 or GLUT1 (Fig. 5). In both 
rats and mice, the overall density of labeled vessels was 
Fig. 1 LAT1 mRNA is expressed in brain microvascular cells and neurons. A To confirm that LAT1 mRNA is expressed in multiple cell types, radioac-
tive LAT1 in situ hybridization (A1 darkfield image, silver grain accumulation represents LAT1 mRNA expression) was combined with dual immu-
nofluorescence (A2) for vimentin (red) and HuC/D (green) to visualize the pericyte coverage of vessels and neuronal cell bodies, respectively. The 
area shown is from the rostral part of the rat hypothalamic supraoptic nucleus (SO). In the merge image (A3), note that silver grains form dense 
clusters over blood vessels (arrows), while a lesser degree of silver grain accumulation is present over neuronal cell bodies (yellow arrowheads). oc 
optic chiasm, SO supraoptic nucleus. B, C LAT1 in situ hybridization was co-localized with LAT1 immunofluorescence (red) that labels the vascular 
endothelium. Note that silver grain clusters that represent high LAT1 mRNA expression are formed over capillaries denoted by LAT1 immunofluo-
rescence (arrows in B3, C3). Images are from the rat hypothalamic ventromedial nucleus (B) and the mouse hypothalamic arcuate nucleus (C). Scale 
bar 50 µm for all images
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Fig. 2 Effect of LPS on LAT1 mRNA expression in brain vessels of rats and mice. A X-ray film images of radioactive LAT1 in situ hybridization in rat 
forebrain sections. Note the reduced “graininess” of the labeling 9 h after LPS, which is especially visible in the thalamus. Neuronal labeling, well vis-
ible in the hippocampus and the hypothalamus, including the dorsomedial nucleus (DMH), is not altered. At 48 h after LPS, the “grainy” signal, which 
represents blood vessels, is more intense than in control brains over the entire section. Cp choroid plexus, DMH dorsomedial hypothalamic nucleus, 
Hip hippocampus, MHb medial habenular nucleus. Scale bar 2 mm. B Darkfield emulsion autoradiography images demonstrate the time course of 
LAT1 mRNA (silver grain accumulation, white) in the rat cortex. In the control cortex, intense hybridization signal is associated with major longitudi-
nal vessels (arrows) and a multitude of small capillaries (numerous bright spots). This labeling vanishes by 4 and 9 h after LPS, only the much lower 
level parenchymal labeling (primarily neuronal) remains. At 48 h after LPS, hybridization signal labels a larger part of the vasculature than in controls, 
including major vessels (arrows) and capillaries. Scale bar 100 µm. C LAT1 mRNA in vessels of the mouse cortex. In the control brain, silver grains 
form clusters over major vessels (arrow) and capillaries, which disappear 9 h after LPS. 48 h after LPS, LAT1 hybridization signal in vessels is more 
intense than in controls. Arrows indicate major vessels. Scale bar 100 µm
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essentially the same following LPS treatment as in con-
trols. In rats, the signal intensity of vessels tended to be 
slightly lower in the 24 h LPS group, but was not signifi-
cantly different from the control group (Figs.  4B, 6A). 
In mice, the brightness of LAT1 immunofluorescence 
in vessels decreased noticeably, albeit only modestly in 
the 24 h and 48 h LPS groups (Fig. 6B). By image analy-
sis, the decrease in the 24  h group was statistically sig-
nificant (Fig. 4C). This reduction of labeling intensity was 
observed in all brain regions, including the cortex, thala-
mus, hypothalamus and amygdala. 
Interestingly, we did not observe clear LAT1 immu-
nostaining in the rat choroid plexus, with the exception 
of a few occasional cells, mostly in the choroid plexus of 
the dorsal third ventricle. This stands in contrast to the 
presence of LAT1 mRNA, and a previous report that 
demonstrated LAT1 immunostaining in the epithe-
lial cells of the rat lateral ventricle choroid plexus [18]. 
However, intense LAT1 immunostaining was present in 
the characteristic choroid plexus-associated cells that 
were labeled with intense LAT1 hybridization signal (see 
Additional file 2).
Fig. 3 LAT1 mRNA decreased in vessels but not in neurons after LPS. A, B Darkfield emulsion autoradiography images show the distribution of 
LAT1 mRNA (silver grain accumulation, white) in the rat hypothalamus. Boxed areas from (A) are shown in higher magnification in (B). Low-level 
hybridization signal is distributed across the arcuate (Arc) and ventromedial nuclei (VMH), highly resembling a neuronal expression pattern; this 
signal does not change following LPS administration. Well-defined silver grains clusters over capillaries disappear 9 h after LPS, but become larger 
and more numerous at 48 h after LPS. 3v third ventricle, Arc, arcuate nucleus, ME median eminence, VMH ventromedial hypothalamic nucleus. Scale 
bar 200 µm on A; 100 µm on B. C LAT1 in situ hybridization signal in the hypothalamic paraventricular nucleus (PVH) of mice. While LAT1 signal 
in capillaries virtually disappears 9 h after LPS, the low-level neuronal LAT1 signal in the paraventricular nucleus remains visible. At 48 h after LPS, 
hybridization signal in vessels is markedly increased. 3v third ventricle, PVH hypothalamic paraventricular nucleus; Scale bar 100 µm
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Effect of LPS on LAT2 mRNA
The pattern of LAT2 mRNA distribution was essen-
tially the same in rats and mice, and corresponded to the 
in situ hybridization pattern described previously in mice 
[12, 19]. Intense neuronal expression was present in the 
cortex, hippocampus, amygdalar regions and numerous 
thalamic nuclei (Fig. 7A). In the hypothalamus, the para-
ventricular and supraoptic nuclei were intensely labeled 
(Fig. 7A), while most other nuclei had no or very low level 
of hybridization signal such as the arcuate and ventrome-
dial nuclei. Moderate to intense expression was observed 
in the choroid plexus of both species (Fig. 7A). LPS did 
not affect LAT2 mRNA expression in either neurons or 
in the choroid plexus in either species (Fig. 7A–C).
Using LAT2 immunofluorescence, we did not observe 
any difference in the pattern or intensity of LAT2-immu-
noreactive labeling between control and LPS-treated 
mice and rats. However, the LAT2 antiserum is not com-
pletely specific to LAT2 in Western blot studies from the 
mouse brain [31], and we were unable to unambiguously 
confirm that the immunostaining patterns were entirely 
specific to LAT2.
Discussion
In the present study, we report that systemic inflamma-
tion, induced by bacterial endotoxin, caused a robust 
decrease in LAT1 mRNA expression at the blood–brain 
barrier of rats and mice. This was followed by an apparent 
rebound effect with increased LAT1 mRNA levels during 
the recovery from endotoxemia. A modest decrease in 
LAT1 protein levels was also observed in mice at 24 h fol-
lowing the LPS stimulus. Neither LAT1 nor LAT2 mRNA 
levels were altered in the choroid plexus or in neurons 
following LPS administration.
With respect to TH homeostasis in the brain, perhaps 
the most important conclusion of the present study is 
that the downregulation of OATP1c1 and MCT8 at the 
blood–brain barrier are not accompanied by a com-
pensatory increase in either LAT1 or LAT2 expression. 
The most remarkable aspect of the results, however, 
is that LPS administration causes strikingly similar 
changes in LAT1, OATP1c1 and MCT8 mRNA lev-
els at the blood–brain barrier. The downregulation of 
LAT1 mRNA in brain vessels occurred essentially at the 
same time course and with the same robustness as that 
of OATP1c1 and MCT8 mRNAs [10]. Moreover, dur-
ing the recovery phase from endotoxemia, LAT1 mRNA 
increased markedly in vessels, which is highly reminis-
cent to the rebound effect we observed for MCT8 and 
OATP1c1 mRNAs between 24  h and 48  h after LPS 
Fig. 4 Semiquantitative image analysis results of LAT1 in situ hybridi-
zation and LAT1 immunofluorescence. A LAT1 hybridization signal 
was quantified in the rat cortex. Values represent area covered by vas-
cular LAT1 hybridization signal. B, C LAT1 immunofluorescence was 
quantified in the rat and mouse hypothalamus, ventro-lateral to the 
hypothalamic paraventricular nucleus. Values represent the average 
brightness value of the immunofluorescence. Groups were compared 
by the non-parametric Kruskal–Wallis test and then by Dunn’s multi-
ple comparison test. *P < 0.05; **P < 0.01; vs control; Samples sizes are 
n = 4 or 5 rats or mice/group
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injection [10]. These parallel changes are somewhat sur-
prising since LAT1 is a high affinity amino acid trans-
porter that accounts for the uptake of large neutral 
amino acids into the brain [32, 33], and regarded only as 
a secondary TH transporter [11]. Thus, these data show 
that two different transport systems of the blood–brain 
barrier, one transporting primarily amino acids (LAT1) 
and the other primarily TH (MCT8 and OATP1c1), are 
regulated in a parallel manner in response to inflamma-
tion. This finding, therefore, raises the question as to 
whether there are other transporters at the blood–brain 
barrier that are similarly regulated in inflammatory con-
ditions. Unfortunately, there are currently no reports in 
the literature about the in  vivo effect of inflammation 
on major blood–brain barrier influx transporters. Inter-
estingly, however, in a very similar LPS model to ours, 
organic anion transporter 3 and organic anion-trans-
porting polypeptide 1a4 protein levels decrease in brain 
capillaries 24 h after LPS injection [34]. Organic anion 
transporter 3 is regarded as a brain-to-blood efflux 
transporter [35], while organic anion-transporting poly-
peptide 1a4 as both an efflux and influx transporter of 
anionic compounds [36]. These data further indicate 
that multiple different transporter systems are down-
regulated at the blood–brain barrier during systemic 
inflammation. Future studies are required to elucidate 
the effect of inflammation on other blood–brain barrier 
transporters.
Fig. 5 LAT1 protein is expressed in cerebral endothelial cells. A1–A3 Dual immunofluorescence for the endothelial marker CD31 (green) and LAT1 
(red) in the mouse brain. LAT1 always colocalized with CD31 in vessels. Some vessels that were labeled for CD31 apparently lacked or had only little 
LAT1 protein expression (arrowhead). Dual immunofluorescence for the endothelial marker GLUT1 (green) and LAT1 (red) and in the mouse (B1–B3) 
and the rat (C1–C3) brain. LAT1 always colocalized with GLUT1 in vessels. A fraction of vessels labeled for GLUT1 were not labeled for LAT1 (arrow-
heads). Scale bar 50 µm
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Given the parallel changes in LAT1, OATP1c1 and 
MCT8 mRNAs in brain vessels, it is reasonable to 
hypothesize that the same cellular mechanism may be 
behind the inflammation-induced down-regulation of 
these genes. Since the expression of these transporters 
remains stable in other brain cell types [10], this mech-
anism may be quite specific to brain endothelial cells. 
Interestingly, LAT1 expression is robustly induced in 
activated human T-cells via the nuclear factor kappa B 
pathway [37], whereas in our LPS model, LAT1 mRNA 
levels decrease in spite of nuclear factor kappa B activa-
tion in cerebral endothelial cells [38, 39]. These data indi-
cate that regulation of LAT1 in brain endothelial cells is 
different than in other cell types of the body.
In contrast to the robust effect on LAT1 mRNA, we 
observed only a modest decrease in LAT1 protein levels 
in mouse brain vessels at 24  h after LPS injection. This 
varies from the robust reduction in OATP1c1 protein lev-
els observed 24 h following LPS, but is similar to MCT8 
protein that remains stable in vessels [10]. The time of 
delay between the decrease in mRNA and protein levels 
probably reflects the half-life of the protein, in this case 
suggesting a high stability for LAT1 protein in brain ves-
sels. Indeed, a half-life of several days is not uncommon 
for plasma membrane proteins [40–47]. Therefore, it is 
conceivable that LAT1 protein in brain vessels is more 
robustly depleted during sustained inflammation caused 
by an actual bacterial infection, the course of which can 
take several days or weeks.
Future studies will also be necessary to determine 
whether LAT1 transport function in brain vessels 
decreases in short-term and/or prolonged inflamma-
tory conditions. The rate of LAT1-mediated amino-acid 
transport across the blood–brain barrier depends on the 
number of functional LAT1 proteins in the luminal and 
abluminal surfaces of endothelial cell membranes [18]. 
LAT1-mediated transport is considered to be saturated 
at physiological serum amino acid concentrations [29, 
48–50]. Therefore, fewer LAT1 proteins in endothelial 
membranes would likely result in reduced LAT1-medi-
ated amino acid transport. It is possible that by the inter-
nalization of LAT1 from the membrane to intracellular 
Fig. 6 LAT1 immunofluorescence in brain vessels of the rat and mouse hypothalamus. A LAT1 immunofluorescence in the rat hypothalamus at the 
level of the paraventricular nucleus (PVH). The intensity of labeling tended to be lower at 24 h after LPS administration. Scale bar 200 µm. B LAT1 
immunofluorescence in hypothalamic vessels of mice; labeling intensity is modestly reduced at 24 and 48 h after LPS. Scale bar 100 µm
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pools, LAT1-mediated transport decreases while the 
amount of LAT1 protein remains stable. Determin-
ing the subcellular distribution of transporters in brain 
endothelial cells is challenging using conventional 
immunofluorescence techniques [18]. As a result, we 
could not determine whether the distribution of LAT1 
shifts between cellular compartments. Nevertheless, our 
results raise the possibility that LAT1 transport func-
tion could decrease, even if only days after the onset of 
inflammation. Since both the amino acids substrates 
of LAT1 and TH are necessary for normal brain func-
tion, their reduced uptake could impede certain neural 
processes, perhaps contributing to reduced cognitive 
function, a general symptom of inflammatory infec-
tions. Whether reduced LAT1 transport is an adaptive 
response following the initial phase of inflammation 
and/or during the actual recovery phase, or maladaptive, 
remains to be understood.
Fig. 7 LPS had no effect on LAT2 mRNA expression in the rat and mouse brain. A X-ray film images of radioactive LAT2 in situ hybridization from 
the rat forebrain. LAT2 is expressed in several neuronal populations and the choroid plexus, but its expression did not change after LPS adminis-
tration. BLA basolateral amygdaloid nucleus, cp choroid plexus, PVH hypothalamic paraventricular nucleus. Scale bar 2 mm. B Darkfield emulsion 
autoradiography images from the rat cortex show no change in neuronal LAT2 mRNA expression after LPS. Scale bar 200 µm. C Similarly, no change 
in LAT2 hybridization signal was observed in neurons of the basolateral amygdaloid nucleus in mice. Scale bar 100 µm
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Conclusions
LPS-induced inflammation caused a robust decrease in 
LAT1 mRNA expression at the blood–brain barrier of 
rodents, and a modest decrease in LAT1 protein content. 
This finding, along with previous results on TH trans-
porters, suggests that systemic inflammation simultane-
ously down-regulates the mRNA expression of different 
transport systems of the blood–brain barrier but the 
kinetics of changes at the level of transporter proteins 
are different. The results imply that the transport rates 
of various substances across the blood–brain barrier, 
such as amino acids and hormones, may be significantly 
altered during inflammation.
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